Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

DBD vs PAX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
DBD
Diebold Nixdorf, Incorporated

Software - Application

TechnologyNYSE • US
Market Cap$2.75B
5Y Perf.+342.8%
PAX
Patria Investments Limited

Asset Management

Financial ServicesNASDAQ • KY
Market Cap$1.92B
5Y Perf.-16.5%

DBD vs PAX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
DBD logoDBD
PAX logoPAX
IndustrySoftware - ApplicationAsset Management
Market Cap$2.75B$1.92B
Revenue (TTM)$3.86B$384M
Net Income (TTM)$110M$86M
Gross Margin26.0%96.2%
Operating Margin8.0%34.2%
Forward P/E14.4x8.4x
Total Debt$1.17B$199M
Cash & Equiv.$387M$54M

DBD vs PAXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

DBD
PAX
StockAug 23May 26Return
Diebold Nixdorf, In… (DBD)100442.8+342.8%
Patria Investments … (PAX)10083.5-16.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: DBD vs PAX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: PAX leads in 6 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Diebold Nixdorf, Incorporated is the stronger pick specifically for recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
DBD
Diebold Nixdorf, Incorporated
The Income Pick

DBD is the clearest fit if your priority is income & stability and long-term compounding.

  • Dividend streak 0 yrs, beta 1.21
  • 289.1% 10Y total return vs PAX's -19.3%
  • +79.3% vs PAX's +14.9%
Best for: income & stability and long-term compounding
PAX
Patria Investments Limited
The Banking Pick

PAX carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.

  • Rev growth 2.6%, EPS growth 14.9%
  • Lower volatility, beta 1.09, Low D/E 31.4%, current ratio 0.98x
  • Beta 1.09, yield 5.0%, current ratio 0.98x
Best for: growth exposure and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthPAX logoPAX2.6% NII/revenue growth vs DBD's 1.5%
ValuePAX logoPAXLower P/E (8.4x vs 14.4x)
Quality / MarginsPAX logoPAX22.3% margin vs DBD's 2.8%
Stability / SafetyPAX logoPAXBeta 1.09 vs DBD's 1.21, lower leverage
DividendsPAX logoPAX5.0% yield; the other pay no meaningful dividend
Momentum (1Y)DBD logoDBD+79.3% vs PAX's +14.9%
Efficiency (ROA)PAX logoPAX6.3% ROA vs DBD's 2.9%, ROIC 12.5% vs 14.0%

DBD vs PAX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

DBDDiebold Nixdorf, Incorporated
FY 2025
Service
57.0%$2.2B
Product
43.0%$1.6B
PAXPatria Investments Limited
FY 2025
Advisory and Other Ancillary Fees
100.0%$10M

DBD vs PAX — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLPAXLAGGINGDBD

Income & Cash Flow (Last 12 Months)

PAX leads this category, winning 4 of 5 comparable metrics.

DBD is the larger business by revenue, generating $3.9B annually — 10.0x PAX's $384M. PAX is the more profitable business, keeping 22.3% of every revenue dollar as net income compared to DBD's 2.8%.

MetricDBD logoDBDDiebold Nixdorf, …PAX logoPAXPatria Investment…
RevenueTrailing 12 months$3.9B$384M
EBITDAEarnings before interest/tax$400M$174M
Net IncomeAfter-tax profit$110M$86M
Free Cash FlowCash after capex$266M$268M
Gross MarginGross profit ÷ Revenue+26.0%+96.2%
Operating MarginEBIT ÷ Revenue+8.0%+34.2%
Net MarginNet income ÷ Revenue+2.8%+22.3%
FCF MarginFCF ÷ Revenue+6.9%+67.3%
Rev. Growth (YoY)Latest quarter vs prior year+6.0%
EPS Growth (YoY)Latest quarter vs prior year+163.6%-40.5%
PAX leads this category, winning 4 of 5 comparable metrics.

Valuation Metrics

Evenly matched — DBD and PAX each lead in 3 of 6 comparable metrics.

At 22.3x trailing earnings, PAX trades at a 28% valuation discount to DBD's 31.1x P/E. On an enterprise value basis, DBD's 7.6x EV/EBITDA is more attractive than PAX's 15.7x.

MetricDBD logoDBDDiebold Nixdorf, …PAX logoPAXPatria Investment…
Market CapShares × price$2.7B$1.9B
Enterprise ValueMkt cap + debt − cash$3.5B$2.1B
Trailing P/EPrice ÷ TTM EPS31.05x22.30x
Forward P/EPrice ÷ next-FY EPS est.14.37x8.42x
PEG RatioP/E ÷ EPS growth rate7.92x
EV / EBITDAEnterprise value multiple7.64x15.74x
Price / SalesMarket cap ÷ Revenue0.72x5.01x
Price / BookPrice ÷ Book value/share2.66x3.00x
Price / FCFMarket cap ÷ FCF10.43x7.44x
Evenly matched — DBD and PAX each lead in 3 of 6 comparable metrics.

Profitability & Efficiency

PAX leads this category, winning 6 of 8 comparable metrics.

PAX delivers a 14.4% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $10 for DBD. PAX carries lower financial leverage with a 0.31x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBD's 1.06x.

MetricDBD logoDBDDiebold Nixdorf, …PAX logoPAXPatria Investment…
ROE (TTM)Return on equity+10.1%+14.4%
ROA (TTM)Return on assets+2.9%+6.3%
ROICReturn on invested capital+14.0%+12.5%
ROCEReturn on capital employed+14.1%+13.9%
Piotroski ScoreFundamental quality 0–966
Debt / EquityFinancial leverage1.06x0.31x
Net DebtTotal debt minus cash$787M$145M
Cash & Equiv.Liquid assets$387M$54M
Total DebtShort + long-term debt$1.2B$199M
Interest CoverageEBIT ÷ Interest expense6.68x7.45x
PAX leads this category, winning 6 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

DBD leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in DBD five years ago would be worth $38,342 today (with dividends reinvested), compared to $10,537 for PAX. Over the past 12 months, DBD leads with a +79.3% total return vs PAX's +14.9%. The 3-year compound annual growth rate (CAGR) favors DBD at 56.5% vs PAX's -0.5% — a key indicator of consistent wealth creation.

MetricDBD logoDBDDiebold Nixdorf, …PAX logoPAXPatria Investment…
YTD ReturnYear-to-date+23.3%-23.4%
1-Year ReturnPast 12 months+79.3%+14.9%
3-Year ReturnCumulative with dividends+283.4%-1.4%
5-Year ReturnCumulative with dividends+283.4%+5.4%
10-Year ReturnCumulative with dividends+289.1%-19.3%
CAGR (3Y)Annualised 3-year return+56.5%-0.5%
DBD leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — DBD and PAX each lead in 1 of 2 comparable metrics.

PAX is the less volatile stock with a 1.09 beta — it tends to amplify market swings less than DBD's 1.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBD currently trades 88.6% from its 52-week high vs PAX's 67.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricDBD logoDBDDiebold Nixdorf, …PAX logoPAXPatria Investment…
Beta (5Y)Sensitivity to S&P 5001.21x1.09x
52-Week HighHighest price in past year$89.05$17.80
52-Week LowLowest price in past year$43.61$10.86
% of 52W HighCurrent price vs 52-week peak+88.6%+67.6%
RSI (14)Momentum oscillator 0–10047.454.1
Avg Volume (50D)Average daily shares traded460K885K
Evenly matched — DBD and PAX each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates DBD as "Buy" and PAX as "Buy". Consensus price targets imply 49.5% upside for PAX (target: $18) vs 26.8% for DBD (target: $100). PAX is the only dividend payer here at 5.00% yield — a key consideration for income-focused portfolios.

MetricDBD logoDBDDiebold Nixdorf, …PAX logoPAXPatria Investment…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$100.00$18.00
# AnalystsCovering analysts135
Dividend YieldAnnual dividend ÷ price+5.0%
Dividend StreakConsecutive years of raises00
Dividend / ShareAnnual DPS$0.60
Buyback YieldShare repurchases ÷ mkt cap+4.8%+2.9%
Insufficient data to determine a leader in this category.
Key Takeaway

PAX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). DBD leads in 1 (Total Returns). 2 tied.

Best OverallPatria Investments Limited (PAX)Leads 2 of 6 categories
Loading custom metrics...

DBD vs PAX: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is DBD or PAX a better buy right now?

For growth investors, Patria Investments Limited (PAX) is the stronger pick with 2.

6% revenue growth year-over-year, versus 1. 5% for Diebold Nixdorf, Incorporated (DBD). Patria Investments Limited (PAX) offers the better valuation at 22. 3x trailing P/E (8. 4x forward), making it the more compelling value choice. Analysts rate Diebold Nixdorf, Incorporated (DBD) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — DBD or PAX?

On trailing P/E, Patria Investments Limited (PAX) is the cheapest at 22.

3x versus Diebold Nixdorf, Incorporated at 31. 1x. On forward P/E, Patria Investments Limited is actually cheaper at 8. 4x.

03

Which is the better long-term investment — DBD or PAX?

Over the past 5 years, Diebold Nixdorf, Incorporated (DBD) delivered a total return of +283.

4%, compared to +5. 4% for Patria Investments Limited (PAX). Over 10 years, the gap is even starker: DBD returned +289. 1% versus PAX's -19. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — DBD or PAX?

By beta (market sensitivity over 5 years), Patria Investments Limited (PAX) is the lower-risk stock at 1.

09β versus Diebold Nixdorf, Incorporated's 1. 21β — meaning DBD is approximately 11% more volatile than PAX relative to the S&P 500. On balance sheet safety, Patria Investments Limited (PAX) carries a lower debt/equity ratio of 31% versus 106% for Diebold Nixdorf, Incorporated — giving it more financial flexibility in a downturn.

05

Which is growing faster — DBD or PAX?

By revenue growth (latest reported year), Patria Investments Limited (PAX) is pulling ahead at 2.

6% versus 1. 5% for Diebold Nixdorf, Incorporated (DBD). On earnings-per-share growth, the picture is similar: Diebold Nixdorf, Incorporated grew EPS 677. 3% year-over-year, compared to 14. 9% for Patria Investments Limited. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — DBD or PAX?

Patria Investments Limited (PAX) is the more profitable company, earning 22.

3% net margin versus 2. 5% for Diebold Nixdorf, Incorporated — meaning it keeps 22. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PAX leads at 34. 2% versus 8. 8% for DBD. At the gross margin level — before operating expenses — PAX leads at 96. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is DBD or PAX more undervalued right now?

On forward earnings alone, Patria Investments Limited (PAX) trades at 8.

4x forward P/E versus 14. 4x for Diebold Nixdorf, Incorporated — 6. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PAX: 49. 5% to $18. 00.

08

Which pays a better dividend — DBD or PAX?

In this comparison, PAX (5.

0% yield) pays a dividend. DBD does not pay a meaningful dividend and should not be held primarily for income.

09

Is DBD or PAX better for a retirement portfolio?

For long-horizon retirement investors, Patria Investments Limited (PAX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

09), 5. 0% yield). Both have compounded well over 10 years (PAX: -19. 3%, DBD: +289. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between DBD and PAX?

These companies operate in different sectors (DBD (Technology) and PAX (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: DBD is a small-cap quality compounder stock; PAX is a small-cap income-oriented stock. PAX pays a dividend while DBD does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

DBD

Quality Business

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 15%
Run This Screen
Stocks Like

PAX

Dividend Mega-Cap Quality

  • Sector: Financial Services
  • Market Cap > $100B
  • Net Margin > 13%
  • Dividend Yield > 2.0%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform DBD and PAX on the metrics below

Revenue Growth>
%
(DBD: 6.0% · PAX: 2.6%)
Net Margin>
%
(DBD: 2.8% · PAX: 22.3%)
P/E Ratio<
x
(DBD: 31.1x · PAX: 22.3x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.